Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $15.38, for a total transaction of $76,900.00. Following the transaction, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at $188,405. The sale was disclosed in a document filed with the SEC, which is available through this link.
Kathy Yi also recently made the following trade(s):
- On Monday, April 16th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $19.83, for a total transaction of $99,150.00.
- On Thursday, March 15th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $25.56, for a total transaction of $127,800.00.
SGMO stock traded down $0.10 during midday trading on Friday, hitting $16.00. The stock had a trading volume of 20,045 shares, compared to its average volume of 2,353,485. The stock has a market capitalization of $1.63 billion, a P/E ratio of -23.00 and a beta of 2.83. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.78 and a current ratio of 4.78. Sangamo Therapeutics Inc has a 12-month low of $15.25 and a 12-month high of $15.65.
Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.29 by ($0.52). The firm had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $53.09 million. Sangamo Therapeutics had a negative return on equity of 30.96% and a negative net margin of 126.96%. The firm’s revenue was up 270.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.23) earnings per share. research analysts forecast that Sangamo Therapeutics Inc will post -0.54 earnings per share for the current fiscal year.
A number of research analysts have recently weighed in on SGMO shares. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, January 24th. Wedbush reaffirmed a “neutral” rating and issued a $6.00 target price on shares of Sangamo Therapeutics in a research note on Monday, February 12th. Jefferies Group reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Barclays reaffirmed a “buy” rating and issued a $30.00 target price on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Finally, ValuEngine raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. Sangamo Therapeutics presently has an average rating of “Hold” and a consensus target price of $21.67.
Hedge funds have recently added to or reduced their stakes in the business. First Mercantile Trust Co. boosted its holdings in shares of Sangamo Therapeutics by 93.7% in the 1st quarter. First Mercantile Trust Co. now owns 7,666 shares of the biopharmaceutical company’s stock valued at $146,000 after purchasing an additional 3,708 shares during the last quarter. Princeton Capital Management LLC acquired a new position in shares of Sangamo Therapeutics in the 1st quarter valued at $149,000. Fred Alger Management Inc. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $148,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Sangamo Therapeutics in the 1st quarter valued at $190,000. Finally, Xact Kapitalforvaltning AB acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at $175,000. 63.74% of the stock is owned by hedge funds and other institutional investors.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.